According to Zheshang's Research Reports, CTIHK (06055) is expected to generate revenue of 13.074 billion HKD in 2024, representing a year-on-year increase of 10.5%, with net income of 0.854 billion HKD, showing a year-on-year growth of 42.6%. This performance exceeds the company's previous profit forecast, which indicated a profit growth of no less than 30%.

The bank indicates that the company continues to adhere to the strategic positioning of capital market operations and international business expansion platforms, actively seeking, screening, and tracking quality symbols, and timely engaging in investment mergers and acquisitions. In terms of organic growth, the focus is on enhancing profitability (through supply chain collaboration, product portfolio optimization, etc.) and expanding the operational areas of cigarettes/CBT/new tobacco.

The bank further notes that as the tobacco industry goes overseas, CTIHK, as a rare platform and industry consolidator, fully benefits. Attention is drawn to the company's internal and external driven performance growth, and it continues to recommend the stock. The bank expects the company's revenue for 2025-2027 to be 14.4 billion, 15.8 billion, and 17.2 billion HKD, respectively, with year-on-year growth rates of 10%, 9%, and 9%. Net income is expected to be 0.958 billion, 1.095 billion, and 1.236 billion HKD, with year-on-year growth rates of 12%, 14%, and 13%, respectively. Corresponding P/E ratios are 17.95X, 15.69X, and 13.91X. Considering the company's rarity and the positive growth curves of each business, the recommendation is to maintain a 'Buy' rating.